Trial Profile
Identification of the risk factors for development of CMV virema associated with low dose Valganciclovir prophylaxis in obese kidney transplant recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2016
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 07 Oct 2016 New trial record